Research ExplorerPublicationsSelf-assembled DNA nanoparticles loaded with Travoprost for ...

Self-assembled DNA nanoparticles loaded with Travoprost for Glaucoma-treatment

Standard

Self-assembled DNA nanoparticles loaded with Travoprost for Glaucoma-treatment. / Schnichels, Sven; Hurst, José; de Vries, Jan Willem; Ullah, Sami; Gruszka, Agnieszka; Kwak, Minseok; Löscher, Marina; Dammeier, Sascha; Bartz-Schmidt, Karl-Ulrich; Spitzer, Martin S; Herrmann, Andreas.

In: NANOMED-NANOTECHNOL, Vol. 29, 10.2020, p. 102260.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Schnichels, S, Hurst, J, de Vries, JW, Ullah, S, Gruszka, A, Kwak, M, Löscher, M, Dammeier, S, Bartz-Schmidt, K-U, Spitzer, MS & Herrmann, A 2020, 'Self-assembled DNA nanoparticles loaded with Travoprost for Glaucoma-treatment', NANOMED-NANOTECHNOL, vol. 29, pp. 102260. https://doi.org/10.1016/j.nano.2020.102260

APA

Schnichels, S., Hurst, J., de Vries, J. W., Ullah, S., Gruszka, A., Kwak, M., Löscher, M., Dammeier, S., Bartz-Schmidt, K-U., Spitzer, M. S., & Herrmann, A. (2020). Self-assembled DNA nanoparticles loaded with Travoprost for Glaucoma-treatment. NANOMED-NANOTECHNOL, 29, 102260. https://doi.org/10.1016/j.nano.2020.102260

Vancouver

Schnichels S, Hurst J, de Vries JW, Ullah S, Gruszka A, Kwak M et al. Self-assembled DNA nanoparticles loaded with Travoprost for Glaucoma-treatment. NANOMED-NANOTECHNOL. 2020 Oct;29:102260. https://doi.org/10.1016/j.nano.2020.102260

Bibtex

@article{9725fc747af04c09aefd32068a70951f,
title = "Self-assembled DNA nanoparticles loaded with Travoprost for Glaucoma-treatment",
abstract = "Lipid DNA nanoparticles (NPs) exhibit an intrinsic affinity to the ocular surface and can be loaded by hybridization with fluorophore-DNA conjugates or with the anti-glaucoma drug travoprost by hybridizing an aptamer that binds the medication. In the travoprost-loaded NPs (Trav-NPs), the drug is bound by specific, non-covalent interactions, not requiring any chemical modification of the active pharmaceutical ingredient. Fluorescently labeled Trav-NPs show a long-lasting adherence to the eye, up to sixty minutes after eye drop instillation. Biosafety of the Trav-NPs was proved and in vivo. Ex vivo and in vivo quantification of travoprost via LC-MS revealed that Trav-NPs deliver at least twice the amount of the drug at every time-point investigated compared to the pristine drug. The data successfully show the applicability of a DNA-based drug delivery system in the field of ophthalmology for the treatment of a major retinal eye disease, i.e. glaucoma.",
author = "Sven Schnichels and Jos{\'e} Hurst and {de Vries}, {Jan Willem} and Sami Ullah and Agnieszka Gruszka and Minseok Kwak and Marina L{\"o}scher and Sascha Dammeier and Karl-Ulrich Bartz-Schmidt and Spitzer, {Martin S} and Andreas Herrmann",
note = "Copyright {\textcopyright} 2020 Elsevier Inc. All rights reserved.",
year = "2020",
month = oct,
doi = "10.1016/j.nano.2020.102260",
language = "English",
volume = "29",
pages = "102260",
journal = "NANOMED-NANOTECHNOL",
issn = "1549-9634",
publisher = "Elsevier Inc.",

}

RIS

TY - JOUR

T1 - Self-assembled DNA nanoparticles loaded with Travoprost for Glaucoma-treatment

AU - Schnichels, Sven

AU - Hurst, José

AU - de Vries, Jan Willem

AU - Ullah, Sami

AU - Gruszka, Agnieszka

AU - Kwak, Minseok

AU - Löscher, Marina

AU - Dammeier, Sascha

AU - Bartz-Schmidt, Karl-Ulrich

AU - Spitzer, Martin S

AU - Herrmann, Andreas

N1 - Copyright © 2020 Elsevier Inc. All rights reserved.

PY - 2020/10

Y1 - 2020/10

N2 - Lipid DNA nanoparticles (NPs) exhibit an intrinsic affinity to the ocular surface and can be loaded by hybridization with fluorophore-DNA conjugates or with the anti-glaucoma drug travoprost by hybridizing an aptamer that binds the medication. In the travoprost-loaded NPs (Trav-NPs), the drug is bound by specific, non-covalent interactions, not requiring any chemical modification of the active pharmaceutical ingredient. Fluorescently labeled Trav-NPs show a long-lasting adherence to the eye, up to sixty minutes after eye drop instillation. Biosafety of the Trav-NPs was proved and in vivo. Ex vivo and in vivo quantification of travoprost via LC-MS revealed that Trav-NPs deliver at least twice the amount of the drug at every time-point investigated compared to the pristine drug. The data successfully show the applicability of a DNA-based drug delivery system in the field of ophthalmology for the treatment of a major retinal eye disease, i.e. glaucoma.

AB - Lipid DNA nanoparticles (NPs) exhibit an intrinsic affinity to the ocular surface and can be loaded by hybridization with fluorophore-DNA conjugates or with the anti-glaucoma drug travoprost by hybridizing an aptamer that binds the medication. In the travoprost-loaded NPs (Trav-NPs), the drug is bound by specific, non-covalent interactions, not requiring any chemical modification of the active pharmaceutical ingredient. Fluorescently labeled Trav-NPs show a long-lasting adherence to the eye, up to sixty minutes after eye drop instillation. Biosafety of the Trav-NPs was proved and in vivo. Ex vivo and in vivo quantification of travoprost via LC-MS revealed that Trav-NPs deliver at least twice the amount of the drug at every time-point investigated compared to the pristine drug. The data successfully show the applicability of a DNA-based drug delivery system in the field of ophthalmology for the treatment of a major retinal eye disease, i.e. glaucoma.

U2 - 10.1016/j.nano.2020.102260

DO - 10.1016/j.nano.2020.102260

M3 - SCORING: Journal article

C2 - 32629041

VL - 29

SP - 102260

JO - NANOMED-NANOTECHNOL

JF - NANOMED-NANOTECHNOL

SN - 1549-9634

ER -